CIDARA THERAPEUTICS, INC.

(CDTX)
  Bericht
Realtime-Estimate Cboe BZX  -  21:45 15.08.2022
0.6550 USD   +3.15%
09.08.Earnings Flash (CDTX) CIDARA THERAPEUTICS erzielt in Q2 einen Umsatz von $6,2 Mio.
MT
09.08.Cidara Therapeutics, Inc. meldet Ergebnis für das zweite Quartal und die sechs Monate bis zum 30. Juni 2022
CI
27.07.Cidara Therapeutics reicht bei der FDA einen Antrag auf ein neues Medikament für Rezafungin ein und unterzeichnet eine Lizenzvereinbarung mit Melinta Therapeutics
MT
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über CIDARA THERAPEUTICS, INC.
10.08.CIDARA THERAPEUTICS : Q2 Earnings Snapshot
10.08.CIDARA THERAPEUTICS : Quarterly Report for Quarter Ending JUNE 30, 2022 (Form 10-Q)
10.08.CIDARA THERAPEUTICS : Provides Corporate Update and Reports Second Quarter 2022 Financial ..
09.08.Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial..
09.08.Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial..
09.08.Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q2 Revenue $6.2M
09.08.CIDARA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
09.08.Cidara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Month..
27.07.Cidara Therapeutics Submits New-Drug Application to FDA for Rezafungin; Signs License D..
27.07.Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Mel..
27.07.CIDARA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events (form..
27.07.Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Mel..
27.07.Cidara Therapeutics, Inc. Enters into License Agreement with Melinta Therapeutics for C..
27.07.Cidara Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Admini..
27.07.Cidara Therapeutics Shares Rise on FDA Application, License Pact
07.07.CIDARA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
07.07.TRANSCRIPT : Cidara Therapeutics, Inc. - Special Call
27.06.Cidara Therapeutics to Host Research and Development Day
27.06.Cidara Therapeutics to Host Research and Development Day
24.06.CIDARA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
11.05.CIDARA THERAPEUTICS : Q1 Earnings Snapshot
11.05.Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $7.1M
11.05.Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ..
11.05.Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ..
11.05.CIDARA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
11.05.Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
26.04.Mundipharma and cidara therapeutics announce first presentation of results from global ..
26.04.Mundipharma and cidara therapeutics announce first presentation of results from global ..
25.04.Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global ..
25.04.Mundipharma and Cidara Therapeutics Announces First Presentation of Results from Global..
14.04.Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Tria..
04.04.CIDARA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
04.04.Cidara Therapeutics, Inc. Announces Executive Changes
31.03.Cidara Therapeutics Says First Cohort Dosed in Phase 1 Trial of Influenza Treatment; Sh..
31.03.Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volu..
31.03.Cidara Therapeutics, Inc. Announces the Completion of Dosing the First Cohort of Health..
24.03.CIDARA THERAPEUTICS : Corporate Presentation - March 2022
07.03.CIDARA THERAPEUTICS : Q4 Earnings Snapshot
07.03.Earnings Flash (CDTX) CIDARA THERAPEUTICS Reports Q4 Revenue $7.2M
07.03.Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year ..
07.03.CIDARA THERAPEUTICS : Provides Corporate Update and Reports Fourth Quarter and Full Year 2..
07.03.Cidara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended Decembe..
07.03.CIDARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
07.03.Cidara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31,..
07.03.Cidara Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
04.03.CIDARA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing ..
04.03.Rezafungin awarded promising innovation medicine (pim) designation by the uk's medicine..
04.03.La rezafungine a reçu le statut de Médicament innovant prometteur (PIM) de l'Agence rég..
03.03.Cidara Therapeutics Gets UK's PIM Label for Rezafungin for Serious Fungal Infection Tre..
03.03.Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK's Medicine..
03.03.Medicines and Healthcare Products Regulatory Agency in the UK Grants Mundipharma and Ci..
14.02.CIDARA THERAPEUTICS : Corporate Presentation - February 2022
14.02.Cidara Says FDA Accepted Investigational New Drug Application for Investigational Influ..
14.02.Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Applicatio..
14.02.Cidara Therapeutics, Inc. Announces FDA Acceptance of its Investigational New Drug Appl..
06.01.Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021CIDARA THERAPEUTICS : Corporate Presentation - December 2021
2021CIDARA THERAPEUTICS : ReSTORE Phase 3 Trial Results for Rezafungin
2021TRANSCRIPT : Cidara Therapeutics, Inc. - Special Call
2021Cidara Therapeutics, Mundipharma Say Fungal Infections Treatment Met Primary Goals in L..
2021Cidara Therapeutics, Inc. and Mundipharma Announce Positive Topline Results from Global..
2021CIDARA THERAPEUTICS : and Mundipharma Announce Positive Topline Results from the Global Ph..
2021Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global P..
2021Certain Common Shares of Cidara Therapeutics, Inc. are subject to a Lock-Up Agreement E..
2021Certain Restricted Stock Units of Cidara Therapeutics, Inc. are subject to a Lock-Up Ag..
2021Certain Warrants of Cidara Therapeutics, Inc. are subject to a Lock-Up Agreement Ending..
2021Cidara Therapeutics Named A San Diego Metro Area Top Workplace For The Fifth Consecutiv..
2021CIDARA THERAPEUTICS : Corporate Presentation - November 2021
2021CIDARA THERAPEUTICS : Q3 Earnings Snapshot
2021Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results - For..
2021CIDARA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
2021Cidara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
2021Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q3 Revenue $7.1M
2021Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results
2021CIDARA THERAPEUTICS : Announces closing of concurrent public offerings of common stock and..
1  2  3  4  5  6  7Weiter
Anstehende Termine für CIDARA THERAPEUTICS, INC.